GLP-1 Medications: A Beginner's Guide – Healthcare Select - MWL

Introduction to GLP-1s

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications that have shown great promise in treating type 2 diabetes and promoting weight loss. These drugs work by mimicking the effects of the naturally occurring hormone GLP-1, which is released by the gut after eating and helps regulate blood sugar and appetite. GLP-1 agonists enhance insulin secretion, slow gastric emptying, reduce food intake, and promote feelings of fullness, making them effective tools for both diabetes management and weight reduction. As the obesity epidemic continues to grow, GLP-1 agonists are emerging as a valuable option for those struggling to lose weight and maintain a healthy lifestyle.

How Do GLP-1 Medications Work?

GLP-1 agonists suppress appetite through multiple mechanisms. They delay gastric emptying, slowing the release of food from the stomach and increasing feelings of fullness. In the brain, GLP-1 receptors are found in the hypothalamus, which regulates food intake. GLP-1 agonists directly stimulate POMC/CART neurons that promote satiety while inhibiting NPY/AgRP neurons involved in hunger, resulting in reduced appetite. Additionally, GLP-1 agonists may alter food reward pathways and decrease cravings for energy-dense foods. Peripheral administration of GLP-1 agonists like liraglutide leads to their uptake in the arcuate nucleus of the hypothalamus, the key region mediating their appetite-suppressing effects.

Benefits of GLP-1 Medications

GLP-1 agonists offer a range of health benefits beyond just blood sugar control and weight loss. They have been shown to improve cardiovascular health by reducing blood pressure, improving lipid profiles, and decreasing inflammation. GLP-1 drugs also promote myocardial glucose uptake and utilization, reduce oxidative stress, and inhibit cardiomyocyte apoptosis, potentially providing cardioprotective effects. Additionally, these medications may strengthen muscles and bones and improve liver, kidney, and lung function. The multifaceted nature of GLP-1 receptor agonists in reducing cardiovascular risk factors and providing direct cardio protection highlights their potential as a comprehensive treatment option for patients with type 2 diabetes and obesity.

Potential Side Effects of GLP-1 Medications

The most common side effects of GLP-1 receptor agonists involve the gastrointestinal system. Nausea, vomiting, diarrhea, and constipation often occur, especially at the beginning of treatment, but tend to diminish over time. More serious but rare adverse effects include pancreatitis, intestinal obstruction, and gastroparesis. There have also been reports of patients on GLP-1 agonists vomiting or aspirating during anesthesia due to the drugs' effect of slowing gastric emptying. Some evidence suggests a potential increased risk of depression and suicidal ideation with these medications. Injection site reactions, headache, and nasopharyngitis are other common side effects that do not usually lead to treatment discontinuation.

Side Effect	Description
Gastrointestinal problems	Nausea, vomiting, diarrhea, and constipation are the most common side effects, especially when starting treatment. These may be severe enough to require stopping the medication.
Injection site reactions	Redness, swelling, and pain at the injection site can occur with injectable GLP-1 agonists, but usually resolve within a few days.
Decreased appetite	A significant but expected side effect that often leads to reduced calorie intake, supporting glycemic control and weight loss goals.
Pancreatitis	GLP-1 agonists may rarely increase the risk of pancreatitis. Monitoring for severe abdominal pain, nausea, and vomiting is important.
Hypoglycemia	Low blood sugar is a risk, particularly when GLP-1 agonists are combined with other diabetes medications like insulin or sulfonylureas.

Table 1: Categories of potential side effects for GLP-1 medication use.

Common GLP-1 Medications

Several GLP-1 agonist medications are currently available for treating type 2 diabetes and obesity. Some common GLP-1 drugs include:

Semaglutide injection (Ozempic and Wegovy)
Semaglutide tablets (Rybelsus)
Liraglutide (Victoza and Saxenda)
Dulaglutide (Trulicity)
Exenatide (Byetta) and extended-release exenatide (Bydureon)
Tirzepatide injection (Mounjaro and Zepbound)

These medications differ in their dosages, route of administration (injection vs oral), additional benefits like cardiovascular protection, approved age range, and tolerability. If one GLP-1 agonist causes intolerable side effects, switching to a different drug in the same class may help.

GLP-1 Clinical Efficacy

GLP-1 receptor agonists vary in their efficacy for glycemic control and weight loss in patients with type 2 diabetes. A recent network meta-analysis found that tirzepatide was the most effective GLP-1 agonist for reducing hemoglobin A1c (mean difference -2.10% vs placebo) and fasting plasma glucose (-3.12 mmol/L vs placebo). For weight loss, CagriSema (semaglutide with cagrilintide) resulted in the highest weight reduction (-14.03 kg vs placebo), followed by tirzepatide (-8.47 kg vs placebo). Semaglutide also effectively lowered LDL cholesterol and total cholesterol. Another meta-analysis showed that albiglutide and subcutaneous semaglutide most significantly reduced major adverse cardiovascular events (MACE) in patients with established cardiovascular disease. In those with heart failure, albiglutide was most effective for reducing MACE, while canagliflozin and liraglutide performed best in patients with chronic kidney disease. Overall, newer GLP-1 agonists like tirzepatide, CagriSema, and semaglutide appear to offer the greatest benefits for glycemic control and weight loss in type 2 diabetes, but the best choice may vary based on individual patient characteristics and comorbidities.

Who is Eligible for GLP-1 Treatment?

GLP-1 receptor agonists are approved for use in adults with type 2 diabetes and those with obesity or overweight with at least one weight-related comorbidity. Patients with a BMI over 30, or over 27 with conditions like high blood pressure, dyslipidemia, sleep apnea, or cardiovascular disease, may be good candidates. GLP-1 therapy can also be considered for diabetic patients who cannot take metformin or are not reaching target blood sugar levels with traditional treatments.

However, GLP-1 agonists are not recommended for pregnant women, individuals with severe gastrointestinal disorders like inflammatory bowel disease, or those at increased risk for certain thyroid cancers. Patients with a history of pancreatitis, kidney failure, or gallbladder disease may also not be suitable candidates. Ultimately, eligibility for GLP-1 treatment should be determined by a healthcare provider based on individual patient factors and potential risks and benefits.

Long-term Weight Maintenance with GLP-1 Therapy

GLP-1 agonists can help patients maintain weight loss long-term, even after stopping the medication. A recent study found that 56.2% of patients who lost weight on semaglutide maintained or continued losing weight one year after stopping treatment, with only 17.7% regaining their starting weight. Patients who combined exercise with GLP-1 agonists had the best results, sustaining both weight loss and body fat reduction one year after stopping the drugs, in contrast to those taking GLP-1 agonists alone. While some weight regain is common after ceasing GLP-1 therapy, most patients maintain a significant portion of their weight loss, especially when they continue lifestyle modifications.

Conclusion

GLP-1 receptor agonists have emerged as a promising treatment option for individuals with type 2 diabetes and obesity, offering significant benefits for glycemic control, weight loss, and cardiovascular health. While these medications are generally well-tolerated, they can cause side effects like gastrointestinal issues and injection site reactions that may require dose adjustments or switching to a different drug in the class. Newer GLP-1 agonists such as semaglutide and tirzepatide appear to be the most effective for reducing blood sugar and body weight, but the best choice depends on individual patient characteristics and comorbidities. As research continues to uncover the multifaceted effects of GLP-1 receptor agonists, these drugs are likely to play an increasingly important role in the comprehensive management of type 2 diabetes and obesity.

References

Introduction

Glucagon Like Peptide 1 - an overview | ScienceDirect Topics. Sciencedirect.com. https://www.sciencedirect.com/topics/medicine-and-dentistry/glucagon-like-peptide-1
Collins, L., & Costello, R. A. (2023). Glucagon-like peptide-1 receptor agonists. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK551568/
Castro, R. (2022, June 29). Do any diabetes drugs help you lose weight? Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/type-2-diabetes/expert-answers/byetta/faq-20057955
Diabetes medicines: GLP-1 agonists - Overview. (2022). Guy’s and St Thomas’ NHS Foundation Trust. https://www.guysandstthomas.nhs.uk/health-information/diabetes-medicines-glp-1-agonists
Elsevier Drug Class Overview | Glucagon-like peptide-1 (GLP-1) receptor agonists. (2024, April 9). Elsevier.health. https://elsevier.health/en-US/preview/glucagon-like-peptide-1-glp-1-receptor-agonists